GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » 3-Year Revenue Growth Rate

Marker Therapeutics (FRA:GX1) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Marker Therapeutics 3-Year Revenue Growth Rate?

Marker Therapeutics's Revenue per Share for the three months ended in Dec. 2024 was €0.69.

During the past 12 months, Marker Therapeutics's average Revenue per Share Growth Rate was 95.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Competitive Comparison of Marker Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Marker Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marker Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's 3-Year Revenue Growth Rate falls into.


;
;

Marker Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Marker Therapeutics  (FRA:GX1) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Marker Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Marker Therapeutics Business Description

Traded in Other Exchanges
Address
9350 Kirby Drive, Suite 300, Houston, TX, USA, 77054
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Marker Therapeutics Headlines

No Headlines